Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.44 |
| ▸ | METAP1 | P53582 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14474743 | 0.86 | NPC1 (0.42) | RAB9ANPC1TGFBR1TGFBR2 | |
| SCHEMBL16183246 | 0.83 | METAP1 (0.45) | METAP2METAP1FFAR1KDM4ELMNA | |
| SCHEMBL14474671 | 0.81 | L3MBTL1 (0.47) | METAP2METAP1FFAR1KDM4ELMNA | |
| SCHEMBL14474140 | 0.81 | LMNA (0.45) | METAP2METAP1FFAR1KDM4ELMNA | |
| SCHEMBL16185147 | 0.79 | FFAR1 (0.43) | METAP2METAP1FFAR1KDM4ELMNA | |
| SCHEMBL16184348 | 0.78 | NPC1 (0.41) | KDM4ERAB9ANPC1TGFBR1TGFBR2 | |
| SCHEMBL16184359 | 0.78 | PIM1 (0.39) | METAP2METAP1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL16184343 | 0.74 | WNT1 (0.41) | ABCG2RAB9ANPC1TGFBR1 | |
| SCHEMBL16185151 | 0.74 | L3MBTL1 (0.45) | METAP2METAP1FFAR1KDM4ELMNA | |
| SCHEMBL16184340 | 0.74 | NPC1 (0.38) | KDM4EHTTSMN1; SMN2RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | METAP2 2043/4885METAP1 1661/4885FFAR1 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.